Patent: 8,454,956
✉ Email this page to a colleague
Summary for Patent: 8,454,956
Title: | Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies |
Abstract: | The invention features methods and compositions for preventing or treating rheumatoid arthritis and osteoporosis by administering an antagonist of IL-20. The IL-20 antagonist may be an anti-IL-20 antibody, such as mAB 7E, that is capable of binding human IL-20 and blocking IL-20 interaction with its receptors. |
Inventor(s): | Chang; Ming-Shi (Tainan, TW) |
Assignee: | National Cheng Kung University (Tainan, TW) |
Application Number: | 12/869,224 |
Patent Claims: | see list of patent claims |
Details for Patent 8,454,956
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2029-08-31 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2029-08-31 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2029-08-31 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2029-08-31 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2029-08-31 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2029-08-31 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | ⤷ Try a Trial | 2029-08-31 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |